Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. - Wikidata - wikimedia - TriplyDB

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.

http://www.wikidata.org/entity/Q34301521

about

Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review Progressive multiple sclerosis Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders Multikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management.ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis.Mast cell and autoimmune diseases.Exploring the cellular basis of human disease through a large-scale mapping of deleterious genes to cell types Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient.Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis Dendritic cells and multiple sclerosis: disease, tolerance and therapy.Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects.Novel therapeutic options for multiple sclerosis.Receptor Tyrosine Kinase and Tyrosine Kinase Inhibitors: New Hope for Success in Multiple Sclerosis Therapy Masitinib for the treatment of mild to moderate Alzheimer's disease.Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?Kinase targets in CNS drug discovery.Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.Role of Mast Cells in the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.Neuroprotective effect of masitinib in rats with postischemic stroke.A Multimodal, Nonpharmacologic Intervention Improves Mood and Cognitive Function in People with Multiple Sclerosis.Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS.Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats.

P2860

Q26782408-AF5ADC56-A1EE-446E-BA90-009BE8D29C84 Q26861772-6DBBC483-BBE4-4F6B-B7FF-15CB5E920C49 Q27000269-B9E7BE40-6E30-427B-B559-A06138D6DB19 Q28068709-4AF486AA-C2F3-4790-B16C-7451D4669DF1 Q29030703-3B671B3D-96BA-4167-91CD-1DADA8CFE9B0 Q29048615-57A3E6DE-8557-4087-93FA-B85C08AE9317 Q30250106-94785E5F-577E-4FFA-A6F9-811C9EDF1A1C Q34554820-7B497016-AABA-4E1B-B20C-8238ADCFC73A Q34599027-F1877165-3B60-4B44-B85C-DA33A15F62A5 Q34677487-DC5D35CB-1570-4D97-8B82-233C54594B4F Q35470932-54E20963-E752-4DD5-AF1C-1F1774503911 Q36020174-2A4AE6F3-7361-4B77-AE03-A07953A3582D Q36085618-D20D28A3-3F3F-4AC5-8670-6493106D6E74 Q36353053-80D9DDCF-1494-48AF-B4F0-74558DD128B6 Q36484443-435E7AE7-93C5-487E-83FD-C2B5C38ADA9B Q37085041-4A4B391E-D747-4EEC-B74A-0D2F3F27823C Q38070093-F6A59F30-B613-4315-B39E-74C77197479C Q38101003-BA412FDC-E8F2-4BF1-B2F3-ABBD615FF84D Q38170129-A2963228-9B45-44E4-AF42-3FB7A4F1CD21 Q38261946-8B8E1B19-BB5A-4C7C-A916-6443FFA73523 Q38472067-C850EC67-FCCE-4ACE-8A27-FF72879CA6D1 Q38534132-9AC8CA87-141E-41BF-BC8F-DBB7025D216E Q38553317-60F17212-ED43-40BC-ADB8-35BF79EF9CC9 Q38760031-939FA0D0-0BCC-40F9-A6A5-528909AE4C75 Q39015818-1AD62395-BC81-42CC-89ED-CA9F1368ACD0 Q39057292-D5D39293-1D8A-40D3-B86A-93467B4220B4 Q43091544-F8BAD2C1-F066-4F87-9B43-5B81A80AA4FA Q47920404-8BD0A915-08CC-44C5-83EA-B327E4F34F88 Q50091408-D137D559-C6FD-4EE4-81AB-6CF666169818 Q52316247-E3357854-B3AD-4444-9C72-515380AE9B34

P2860

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.

http://www.wikidata.org/entity/Q34301521

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Masitinib treatment in patient ...... sis: a randomized pilot study.

@ast

Masitinib treatment in patient ...... sis: a randomized pilot study.

@en

Masitinib treatment in patient ...... sis: a randomized pilot study.

@nl

type

label

Masitinib treatment in patient ...... sis: a randomized pilot study.

@ast

Masitinib treatment in patient ...... sis: a randomized pilot study.

@en

Masitinib treatment in patient ...... sis: a randomized pilot study.

@nl

prefLabel

Masitinib treatment in patient ...... sis: a randomized pilot study.

@ast

Masitinib treatment in patient ...... sis: a randomized pilot study.

@en

Masitinib treatment in patient ...... sis: a randomized pilot study.

@nl

P1433

Q34301521-262716BE-88E2-45B2-A776-3C4FA82AE50F

P1476

Q34301521-BE0F1B60-AE25-4186-B06F-184E89D6CB0F

P2093

Q34301521-33C18ECD-92AB-4F0F-B344-3015AA76CEF7

Q34301521-41C16879-B41D-462E-A729-83AC49A121FC

Q34301521-7DBE054F-05DA-4E24-B99E-92CC1CE7A58E

Q34301521-B5C40499-1677-4AA9-9738-BD8737A8EA37

Q34301521-DA8FCB26-8A56-49F2-830E-C16D4EC45F79

Q34301521-E3FFBE50-6441-4D64-ADE1-47776A739B2A

Q34301521-FF7DF035-1D77-4179-B0A6-099D94D6A71C

P2860

Q34301521-006A3BDD-98A0-458C-B61A-70E8AD79FA49

Q34301521-2C7F81C0-A0BD-4F48-A458-ADDC4886E25C

Q34301521-369B4CBF-5822-44A4-A733-CCE8D8362CD9

Q34301521-433126F5-173B-4078-BAA5-640C2B98F8F3

Q34301521-456AC1D2-5106-43B9-A532-986CCCB8573D

Q34301521-46ECF723-C930-41CB-A8F1-C446CA068A9D

Q34301521-49B0F272-AC9E-4D29-9F56-2A2DDAF487DE

Q34301521-4BBA3D07-D075-4FED-A0A2-B786857508D5

Q34301521-55C40954-4943-4DF5-BAB9-78FA4F0127B3

Q34301521-64B3291E-A4F5-464E-A462-EA3FE2280778

P2888

Q34301521-2E8D23AC-39D7-4315-9843-58018E1A49E0

P304

Q34301521-FDFDF26C-D05C-4AA4-85EA-743989D0AC09

P31

Q34301521-F518A095-C0F6-4084-8998-4A0753EC4BE8

P356

Q34301521-785F3676-1BF1-43B1-A189-7D04AC424290

P478

Q34301521-C84F6692-56B2-4EE1-A72B-98D3B3C9545E

P50

Q34301521-53F5E037-25E0-4B05-9221-910C5154542B

Q34301521-C1946BB0-9BA4-4A99-B0C6-D27370D811AC

P577

Q34301521-83F137E8-8943-44E8-81C2-22EBB6563722

P5875

Q34301521-138290B0-CF3F-4046-847E-B68170C97CBA

P6179

Q34301521-3553F8E5-9AC5-4FDA-A997-7514EDF12831

P698

Q34301521-3E6841D4-058A-4C9C-A17A-5E9FBF5227CC

P921

Q34301521-7C932909-BA3A-4979-81A8-472F7AC705F7

Q34301521-CC2030DB-206E-4F24-8732-E6A725D52889

P932

Q34301521-44A456F2-66A1-4A8F-9476-48F30F48134E

P356

1471-2377-12-36

P1433

P1476

Masitinib treatment in patient ...... sis: a randomized pilot study.

@en

P2093

Alain Moussy

http://www.w3.org/2001/XMLSchema#string

Cyrille Vongsouthi

http://www.w3.org/2001/XMLSchema#string

Hélène Zéphir

http://www.w3.org/2001/XMLSchema#string

Nicolas Schmidt

http://www.w3.org/2001/XMLSchema#string

Patrick Vermersch

http://www.w3.org/2001/XMLSchema#string

Pierre Clavelou

http://www.w3.org/2001/XMLSchema#string

Rabah Benrabah

http://www.w3.org/2001/XMLSchema#string

P2860

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

Defining the clinical course of multiple sclerosis: Results of an international survey

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma

The Lyn tyrosine kinase differentially regulates dendritic cell generation and maturation

Multiple sclerosis

Brain mast cells link the immune system to anxiety-like behavior.

P2888

1471-2377-12-36

P304

36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2377-12-36

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Olivier Hermine

Patrice Dubreuil

P577

2012-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225300242

http://www.w3.org/2001/XMLSchema#string

P6179

1026741426

http://www.w3.org/2001/XMLSchema#string

P698

22691628

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

3467179

http://www.w3.org/2001/XMLSchema#string